Department of Neurology, University Hospital of Strasbourg, 67091 Strasbourg, France.
Neurology. 2010 Mar 2;74(9):736-42. doi: 10.1212/WNL.0b013e3181d31e35.
There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients.
We performed an observational, retrospective, multicenter study. Data were collected from September 2007 through August 2008, corresponding to the endpoint of the study. We identified 125 patients fulfilling the 2006 NMO criteria. Selection was made using hospital files and a specific clinical questionnaire for NMO.
Mean age at onset was 34.5 years (range 4-66) with a mean disease duration of 10 +/- 7.8 years at the endpoint. The patients were mainly (87%) Caucasian, with a female:male ratio of 3:1. In 90% of cases, the association of optic neuritis, longitudinal extensive myelitis, and a Paty-negative initial brain MRI was sufficient to fulfill the supportive criteria. Eighty-eight percent of patients were treated with immunosuppressive therapies. Median delay from onset to Expanded Disability Status Scale (EDSS) score 4 was 7 years; score 6, 10 years; and score 7, 21 years. The first episode of myelitis was immediately followed by an EDSS score > or = 4 in 37.3% of cases, and a severe residual visual loss was observed in 22% of patients after the first episode of optic neuritis. Multivariate analysis did not reveal any predictors of a poor evolution other than a high number of MRI brain lesions at diagnosis, which were predictive of a residual visual acuity < or = 1/10.
Our demographic data provide new data on disability in patients with neuromyelitis optica, most of whom were receiving treatment.
已有少数几项关于视神经脊髓炎(NMO)的流行病学研究,但都没有使用最近的 2006 年诊断标准。在此,我们描述了法国的 125 例 NMO 患者的临床、实验室、磁共振成像(MRI)和残疾病程。
我们进行了一项观察性、回顾性、多中心研究。数据于 2007 年 9 月至 2008 年 8 月收集,对应研究的终点。我们确定了 125 例符合 2006 年 NMO 标准的患者。通过医院病历和 NMO 专用临床问卷进行选择。
发病时的平均年龄为 34.5 岁(范围 4-66),终点时的平均病程为 10±7.8 年。患者主要为(87%)白种人,女性与男性比例为 3:1。在 90%的病例中,视神经炎、纵向广泛脊髓炎和 Paty 阴性的初始脑 MRI 联合足以满足支持标准。88%的患者接受免疫抑制治疗。从发病到扩展残疾状态量表(EDSS)评分 4 的中位延迟为 7 年;评分 6 的中位延迟为 10 年;评分 7 的中位延迟为 21 年。首次脊髓炎后立即出现 EDSS 评分≥4 的占 37.3%,首次视神经炎后有 22%的患者出现严重的残余视力丧失。多变量分析显示,除诊断时脑 MRI 病变数量较多外,没有任何不良预后的预测因素,脑 MRI 病变数量多预示着残余视力<或=1/10。
我们的人口统计学数据为视神经脊髓炎患者的残疾情况提供了新的资料,其中大多数患者正在接受治疗。